BidaskClub Lowers Alder BioPharmaceuticals (ALDR) to Strong Sell

BidaskClub cut shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a sell rating to a strong sell rating in a research note issued to investors on Tuesday, December 19th.

Other equities research analysts have also recently issued research reports about the stock. Credit Suisse Group set a $11.00 target price on shares of Alder BioPharmaceuticals and gave the stock a hold rating in a research note on Thursday, August 24th. Canaccord Genuity started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, October 26th. They set a buy rating and a $20.00 price target on the stock. Royal Bank of Canada started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating and a $17.00 price target on the stock. Cowen started coverage on shares of Alder BioPharmaceuticals in a research report on Tuesday, September 26th. They set an outperform rating and a $20.00 price target on the stock. Finally, Mizuho reissued a buy rating and set a $32.00 price target on shares of Alder BioPharmaceuticals in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $27.79.

Shares of Alder BioPharmaceuticals (ALDR) traded up $0.55 on Tuesday, reaching $17.90. 1,575,700 shares of the company’s stock traded hands, compared to its average volume of 2,602,860. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $25.45. The firm has a market cap of $1,210.00, a PE ratio of -3.33 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.29. During the same quarter last year, the firm posted ($0.70) EPS. sell-side analysts expect that Alder BioPharmaceuticals will post -5.14 EPS for the current fiscal year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $10.80, for a total transaction of $178,405.20. Following the sale, the insider now directly owns 116,451 shares in the company, valued at $1,257,670.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.60% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC purchased a new stake in shares of Alder BioPharmaceuticals during the third quarter worth approximately $132,000. Jane Street Group LLC purchased a new stake in shares of Alder BioPharmaceuticals during the third quarter worth approximately $184,000. Legal & General Group Plc increased its stake in shares of Alder BioPharmaceuticals by 2.6% during the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 400 shares during the period. SG Americas Securities LLC increased its stake in shares of Alder BioPharmaceuticals by 109.4% during the second quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 8,140 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in Alder BioPharmaceuticals by 8.4% in the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 1,734 shares in the last quarter. Hedge funds and other institutional investors own 96.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Lowers Alder BioPharmaceuticals (ALDR) to Strong Sell” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/alder-biopharmaceuticals-aldr-downgraded-to-strong-sell-at-bidaskclub.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply